青蒿琥酯对高糖条件下血管内皮细胞ICAM-1和MMP-9表达的影响
Effect of Artesunate on the Expression of ICAM-1 and MMP-9 in Vascular Endothelial Cells under High Glucose Condition
摘要: 目的:探讨ART对高糖条件下血管内皮细胞ICAM-1和MMP-9表达的影响。方法:将人脐静脉内皮细胞(Human Umbilical Vein Endothelial Cells, HUVEC)作为实验对象,分为葡萄糖(Glucose, G)组、40 mmol/L G + ART (G40 + ART)组,甘露醇(Mannitol, M)对照组、G40 + DMSO (DMSO)对照组,其中G组浓度梯度分为5.5 mmol/L G(G5.5)、25 mmol/L G(G25)、40 mmol/L G(G40);M对照组浓度梯度为5.5 mmol/L G + 19.5 mmol/L M(M25),5.5 mmol/L G + 34.5 mmol/L M(M40),G40 + ART组中依据ART浓度梯度分为G40 + 10 ug/ml ART(10A)、G40 + 20 ug/ml ART(20A)、G40 + 40 ug/ml ART(40A);DMSO对照组中DMSO用量与40A组中溶解ART所用DMSO体积相同。采用Western blot、细胞免疫荧光技术分别检测各组细胞间黏附分子-1(ICAM-1)、基质金属蛋白酶-9(MMP-9)蛋白表达情况。结果:1) ICAM-1、MMP-9蛋白在G25组较G5.5组表达升高(P < 0.01),且G40组较G25组表达升高(P < 0.01);ICAM-1、MMP-9蛋白在G40 + ART组较G40组表达下降,其中,10A组低于G40组(P < 0.01),20A组低于10A组(P < 0.01),40A组低于20A组(P < 0.01)。2) ICAM-1、MMP-9蛋白在G25组较M25组表达升高(P < 0.01);G40组较M40组表达升高(P < 0.01)。3) DMSO对照组显示G40 + ART组ICAM-1、MMP-9蛋白表达低于DMSO组(P < 0.01)。结论:ICAM-1和MMP-9蛋白在高糖条件下表达升高,且具有浓度依赖性,ART可抑制高糖条件下血管内皮细胞ICAM-1和MMP-9蛋白的表达,且具有浓度依赖性,为进一步研究ART抑制视网膜新生血管形成和渗漏的机制中ICAM-1和MMP-9表达变化奠定基础。
Abstract: Objective: To investigate the effect of ART on the expression of ICAM-1 and MMP-9 in vascular en-dothelial cells under high glucose condition. Methods: Human Umbilical Vein Endothelial Cells (HUVEC) were divided into glucose (G) group, 40 mmol/L G + ART (G40 + ART) group, mannitol (M) control group, dimethyl sulfoxide (DMSO) control group. The concentration gradient of G group is 5.5 mmol/L G (G5.5), 25 mmol/L G (G25), 40 mmol/L G (G40); the concentration gradient of M control group is 5.5 mmol/L G + 19.5 mmol/L M (M25), 5.5 mmol/L G + 34.5 mmol/L M (M40); the concentration gradient of ART of G40 + ART group is G40 + 10 ug /ml ART (10A), G40 + 20 ug/ml ART (20A), G40 + 40 ug/ml ART (40A); the volume of DMSO in the DMSO control group is the same as it is in the 40A group. Western blot and cell immunofluorescence technique were used to detect the protein expression of Intercellular adhesion molecule-1 (ICAM-1) and Matrix metalloproteinase-9 (MMP-9) in each group. Results: The protein expression of ICAM-1 and MMP-9 in G25 group was higher than that in G5.5 group (P < 0.01), and it increased in G40 group compared with G25 group (P < 0.01); the protein expression of ICAM-1 and MMP-9 in G25 group was higher than that of M25 group (P < 0.01), and it increased in G40 group compared with M40 (P < 0.01); the protein expression of ICAM-1 and MMP-9 of G40 + ART group was lower than that of G40 group, in which it was lower in 20A group than that of 10A group (P < 0.01), and it was lower in 40A group compared with 20A group (P < 0.01). The DMSO control group showed that the protein expression of ICAM-1 and MMP-9 in G40 + ART was lower than that of G40 + DMSO group (P < 0.01). Conclusion: The expression of ICAM-1 and MMP-9 protein was increased under high glucose condition in a concentration-dependent manner. ART inhibited the expression of ICAM-1 and MMP-9 protein in vascular endothelial cells under high glucose condition in a concentration-dependent manner. This experiment lays the foundation for further study of the changes of ICAM-1 and MMP-9 expression in the mechanism of ART inhibiting retinal neovascularization and leakage.
文章引用:葛朋飞, 姜涛, 宗瑶, 杨雪娇, 马玉娜, 王云霄, 孙哲, 曹子群. 青蒿琥酯对高糖条件下血管内皮细胞ICAM-1和MMP-9表达的影响[J]. 眼科学, 2019, 8(1): 41-51. https://doi.org/10.12677/HJO.2019.81008

参考文献

[1] Rubsam, A., Parikh, S. and Fort, P.E. (2018) Role of Inflammation in Diabetic Retinopathy. International Journal of Molecular Sciences, 19, 942.
[Google Scholar] [CrossRef] [PubMed]
[2] Stefanini, F.R., Badaro, E., Falabella, P., et al. (2014) Anti-VEGF for the Management of Diabetic Macular Edema. Journal of Immunology Research, 2014, Article ID: 632307.
[Google Scholar] [CrossRef] [PubMed]
[3] Barber, A.J. (2003) A New View of Diabetic Ret-inopathy: A Neurodegenerative Disease of the Eye. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27, 283-290.
[Google Scholar] [CrossRef
[4] He, R.R. and Zhou, H.J. (2008) Progress in Research on the Anti-Tumor Effect of Artesunate. Chinese Journal of Integrative Medicine, 14, 312-316.
[Google Scholar] [CrossRef] [PubMed]
[5] Chen, H.H. and Zhou, H.J. (2004) Inhibitory Effects of Ar-tesunate on Angiogenesis. Acta Pharmaceutica Sinica, 39, 29-33.
[6] Zong, Y., Yuan, Y., Qian, X., et al. (2016) Small Molecular-Sized Artesunate Attenuates Ocular Neovascularization via VEGFR2, PKCalpha, and PDGFR Targets. Scientific Reports, 6, Article No. 30843.
[Google Scholar] [CrossRef] [PubMed]
[7] Rocca, A., Tafuri, D., Paccone, M., et al. (2017) Cell Based Therapeutic Approach in Vascular Surgery: Application and Review. Open Medicine (Warsaw, Poland), 12, 308-322.
[Google Scholar] [CrossRef] [PubMed]
[8] Kowluru, R.A., Zhong, Q. and Santos, J.M. (2012) Matrix Metallo-proteinases in Diabetic Retinopathy: Potential Role of MMP-9. Expert Opinion on Investigational Drugs, 21, 797-805.
[Google Scholar] [CrossRef] [PubMed]
[9] Cronstein, B.N. and Weissmann, G. (1993) The Adhesion Molecules of Inflammation. Arthritis and Rheumatism, 36, 147-157.
[Google Scholar] [CrossRef] [PubMed]
[10] Mackay, C.R. and Imhof, B.A. (1993) Cell Adhesion in the Immune System. Immunology Today, 14, 99-102.
[Google Scholar] [CrossRef
[11] Schroder, S., Palinski, W. and Schmid-Schonbein, G.W. (1991) Activated Monocytes and Granulocytes, Capillary Nonperfusion, and Neovascularization in Diabetic Retinopathy. The American Journal of Pathology, 139, 81-100.
[12] Joussen, A.M., Murata, T., Tsujikawa, A., et al. (2001) Leukocyte-Mediated Endothelial Cell Injury and Death in the Diabetic Retina. The American Journal of Pathology, 158, 147-152.
[Google Scholar] [CrossRef
[13] Adamis, A.P., Shima, D.T., Tolentino, M.J., et al. (1996) Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate. Archives of Ophthalmology, 114, 66-71.
[Google Scholar] [CrossRef] [PubMed]
[14] Aiello, L.P., Pierce, E.A., Foley, E.D., et al. (1995) Suppression of Retinal Neovascularization in Vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins. Proceedings of the National Academy of Sciences of the United States of America, 92, 10457-10461.
[Google Scholar] [CrossRef] [PubMed]
[15] Adamis, A.P. (2002) Is Diabetic Retinopathy an Inflammatory Disease? The British Journal of Ophthalmology, 86, 363-365.
[Google Scholar] [CrossRef] [PubMed]
[16] Joussen, A.M., Poulaki, V., Le, M.L., et al. (2004) A Central Role for Inflammation in the Pathogenesis of Diabetic Retinopathy. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 18, 1450-1452.
[Google Scholar] [CrossRef] [PubMed]
[17] El-Asrar, A.M. (2012) Role of Inflammation in the Pathogenesis of Diabetic Retinopathy. Middle East African Journal of Ophthalmology, 19, 70-74.
[Google Scholar] [CrossRef] [PubMed]
[18] Steeber, D.A., Campbell, M.A., Basit, A., et al. (1998) Optimal Selectin-Mediated Rolling of Leukocytes during Inflammation in Vivo Requires Intercellular Adhesion Molecule-1 Expression. Proceedings of the National Academy of Sciences of the United States of America, 95, 7562-7567.
[Google Scholar] [CrossRef] [PubMed]
[19] Williams, M.R. and Luscinskas, F.W. (2011) Leukocyte Rolling and Adhesion via ICAM-1 Signals to Endothelial Permeability. Focus on “Leukocyte Rolling and Adhesion both Contribute to Regulation of Microvascular Permeability to Albumin via Ligation of ICAM-1”. American Journal of Physiology. Cell Physiology, 301, C777-C779.
[Google Scholar] [CrossRef] [PubMed]
[20] Joussen, A.M., Poulaki, V., Mitsiades, N., et al. (2003) Suppres-sion of Fas-FasL-Induced Endothelial Cell Apoptosis Prevents Diabetic Blood-Retinal Barrier Breakdown in a Model of Streptozotocin-Induced Diabetes. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 17, 76-78.
[Google Scholar] [CrossRef] [PubMed]
[21] Rangasamy, S., McGuire, P.G. and Das, A. (2012) Diabetic Retinopathy and Inflammation: Novel Therapeutic Targets. Middle East African journal of ophthalmology, 19, 52-59.
[Google Scholar] [CrossRef] [PubMed]
[22] Ram, M., Sherer, Y. and Shoenfeld, Y. (2006) Matrix Metallo-proteinase-9 and Autoimmune Diseases. Journal of Clinical Immunology, 26, 299-307.
[Google Scholar] [CrossRef] [PubMed]
[23] Malemud, C.J. (2006) Matrix Metalloproteinases (MMPs) in Health and Disease: An Overview. Frontiers in Bioscience: A Journal and Virtual Library, 11, 1696-1701.
[24] Giebel, S.J., Menicucci, G., McGuire, P.G., et al. (2005) Matrix Metalloproteinases in Early Diabetic Retinopathy and Their Role in Alteration of the Blood-Retinal Barrier. Laboratory Investigation: A Journal of Technical Methods and Pathology, 85, 597-607.
[Google Scholar] [CrossRef] [PubMed]
[25] Matsumoto, K., Sera, Y., Ueki, Y., et al. (2002) Comparison of Serum Concentrations of Soluble Adhesion Molecules in Diabetic Microangiopathy and Macroangiopathy. Diabetic Medicine: A Journal of the British Diabetic Association, 19, 822-826.
[Google Scholar] [CrossRef] [PubMed]
[26] Limb, G.A., Hickman-Casey, J., Hollifield, R.D., et al. (1999) Vascular Adhesion Molecules in Vitreous from Eyes with Proliferative Diabetic Retinopathy. Investigative Ophthalmology & Visual Science, 40, 2453-2457.
[27] Das, A., McGuire, P.G., Eriqat, C., et al. (1999) Human Dia-betic Neovascular Membranes Contain High Levels of Urokinase and Metalloproteinase Enzymes. Investigative Oph-thalmology & Visual Science, 40, 809-813.
[28] Lee, C.H., Shieh, Y.S., Hsiao, F.C., et al. (2014) High Glucose In-duces Human Endothelial Dysfunction through an Axl-Dependent Mechanism. Cardiovascular Diabetology, 13, 53.
[Google Scholar] [CrossRef] [PubMed]
[29] Song, H., Wang, L. and Hui, Y. (2007) Expression of CD18 on the Neutrophils of Patients with Diabetic Retinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology, 245, 24-31.
[Google Scholar] [CrossRef] [PubMed]
[30] Kociok, N., Radetzky, S., Krohne, T.U., et al. (2009) ICAM-1 Depletion Does Not Alter Retinal Vascular Development in a Model of Oxygen-Mediated Neovascularization. Exper-imental Eye Research, 89, 503-510.
[Google Scholar] [CrossRef] [PubMed]
[31] Bhatt, L.K. and Addepalli, V. (2010) Attenuation of Diabetic Retinopathy by Enhanced Inhibition of MMP-2 and MMP-9 Using Aspirin and Minocycline in Streptozotocin-Diabetic Rats. American Journal of Translational Research, 2, 181-189.
[32] Samtani, S., Amaral, J., Campos, M.M., et al. (2009) Doxycycline-Mediated Inhibition of Choroidal Neovascularization. Investigative Ophthalmology & Visual Science, 50, 5098-5106.
[Google Scholar] [CrossRef] [PubMed]
[33] (2015) VEGF Inhibitors for AMD and Diabetic Macular Edema. JAMA, 314, 2184-2185.
[Google Scholar] [CrossRef] [PubMed]
[34] Klaassen, I., Van Noorden, C.J. and Schlingemann, R.O. (2013) Molecular Basis of the Inner Blood-Retinal Barrier and Its Breakdown in Diabetic Macular Edema and Other Pathological Conditions. Progress in Retinal and Eye Research, 34, 19-48.
[Google Scholar] [CrossRef] [PubMed]
[35] Yu, Y., Yang, L., Lv, J., et al. (2015) The Role of High Mobility Group Box 1 (HMGB-1) in the Diabetic Retinopathy Inflammation and Apoptosis. International Journal of Clinical and Experimental Pathology, 8, 6807-6813.
[36] Santos, A.R., Dvoriantchikova, G., Li, Y., et al. (2014) Cellular Mechanisms of High Mobility Group 1 (HMGB-1) Protein Action in the Diabetic Retinopathy. PLoS ONE, 9, e87574.
[Google Scholar] [CrossRef] [PubMed]
[37] Clauss, M., Sunderkotter, C., Sveinbjornsson, B., et al. (2001) A Permissive Role for Tumor Necrosis Factor in Vascular Endothelial Growth Factor-Induced Vascular Permeability. Blood, 97, 1321-1329.
[Google Scholar] [CrossRef
[38] Joussen, A.M., Poulaki, V., Mitsiades, N., et al. (2002) Non-steroidal Anti-Inflammatory Drugs Prevent Early Diabetic Retinopathy via TNF-Alpha Suppression. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 16, 438-440.
[Google Scholar] [CrossRef] [PubMed]
[39] Jampol, L.M., Bressler, N.M. and Glassman, A.R. (2014) Revolution to a New Standard Treatment of Diabetic Macular Edema. JAMA, 311, 2269-2270.
[Google Scholar] [CrossRef] [PubMed]
[40] Lu, X. and Sun, X. (2015) Profile of Conbercept in the Treatment of Neovascular Age-Related Macular Degeneration. Drug Design, Development and Therapy, 9, 2311-2320.
[41] Wong, T.Y., Liew, G. and Mitchell, P. (2007) Clinical Update: New Treatments for Age-Related Macular Degeneration. The Lancet (London, England), 370, 204-206.
[Google Scholar] [CrossRef
[42] Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. (2012) Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology, 119, 789-801.
[Google Scholar] [CrossRef] [PubMed]
[43] Rajendram, R., Fraser-Bell, S., Kaines, A., et al. (2012) A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Man-agement of Diabetic Macular Edema: 24-Month Data: Report 3. Archives of Ophthalmology, 130, 972-979.
[Google Scholar] [CrossRef] [PubMed]
[44] Brown, D.M., Schmidt-Erfurth, U., Do, D.V., et al. (2015) Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results from the VISTA and VIVID Studies. Oph-thalmology, 122, 2044-2052.
[Google Scholar] [CrossRef] [PubMed]
[45] Michael, S. and Ip, M.D. (2008) A Randomized Trial Com-paring Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema. Ophthal-mology, 115, 1447-1449.
[46] Ebneter, A. and Zinkernagel, M.S. (2016) Novelties in Diabetic Retinopathy. Endocrine Development, 31, 84-96.
[Google Scholar] [CrossRef] [PubMed]
[47] Zang, M., Zhu, F., Zhao, L., et al. (2014) The Effect of UGTs Polymor-phism on the Auto-Induction Phase II Metabolism-Mediated Pharmacokinetics of Dihydroartemisinin in Healthy Chinese Subjects after Oral Administration of a Fixed Combination of Dihydroartemisinin-Piperaquine. Malaria Journal, 13, 478.
[Google Scholar] [CrossRef] [PubMed]
[48] Efferth, T., Sauerbrey, A., Olbrich, A., et al. (2003) Molecular Modes of Action of Artesunate in Tumor Cell Lines. Molecular Pharmacology, 64, 382-394.
[Google Scholar] [CrossRef] [PubMed]
[49] Berger, T.G., Dieckmann, D., Efferth, T., et al. (2005) Artesunate in the Treatment of Metastatic Uveal Melanoma—First Experiences. Oncology Reports, 14, 1599-1603.
[Google Scholar] [CrossRef
[50] White, N.J., Ashley, E.A. and Nosten, F. (2006) Toxic Brainstem En-cephalopathy after Artemisinin Treatment for Breast Cancer. Annals of Neurology, 59, 725-726.
[Google Scholar] [CrossRef] [PubMed]
[51] Crespo-Ortiz, M.P. and Wei, M.Q. (2012) Antitumor Activity of Arte-misinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug. Journal of Biomed-icine & Biotechnology, 2012, Article ID: 247597.
[Google Scholar] [CrossRef] [PubMed]
[52] Ba, Q., Duan, J., Tian, J.Q., et al. (2013) Dihydroartemisinin Promotes Angiogenesis during the Early Embryonic Development of Zebrafish. Acta Pharmacologica Sinica, 34, 1101-1107.
[Google Scholar] [CrossRef] [PubMed]
[53] D’Alessandro, S., Gelati, M., Basilico, N., et al. (2007) Differential Ef-fects on Angiogenesis of Two Antimalarial Compounds, Dihydroartemisinin and Artemisone: Implications for Embry-otoxicity. Toxicology, 241, 66-74.
[Google Scholar] [CrossRef] [PubMed]